Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 22%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
Leverage ratios is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
How much the company owes, how it's trended, and how comfortably it's serviced.
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~3.1% on $1.88B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Ranked against 12 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNH | $365.3B | 30.8× | 21.0× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 2.7× | 1,148 |
| ELV | $91.1B | 16.7× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 2.9× | 482 |
| CI | $78.8B | 13.4× | 8.6× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 8.1% | 2.0× | 494 |
| AFL | $62.1B | 18.2× | — | 3.6× | -9.3% | — | 21.2% | 12.4% | 12.4% | — | 557 |
| HUM | $49.8B | 42.1× | 16.7× | 0.4× | 10.1% | — | 0.9% | 6.7% | 4.0% | 2.4× | 261 |
| CNC | $33.9B | — | — | 0.2× | 19.4% | 7.3% | -3.4% | -33.4% | -17.9% | — | 292 |
| PFG | $23.7B | 21.3× | — | 1.5× | -3.1% | — | 7.6% | 10.0% | 7.5% | — | 285 |
| UNM | $14.4B | 21.3× | — | 1.1× | 1.5% | — | 5.6% | 6.6% | 5.0% | — | 199 |
| MOH | $10.6B | 23.0× | 10.4× | 0.2× | 11.7% | 13.1% | 1.0% | 11.6% | 6.0% | -0.5× | 142 |
| CNO | $5.3B | 25.1× | 6.1× | 1.2× | 0.9% | — | 5.1% | 8.7% | 8.7% | 0.0× | — |
| ALHC | $1.5B | — | 28.1× | 0.4× | 46.1% | — | -0.0% | -0.4% | -0.1% | -5.6× | 48 |
| PREJF | $1.5B | — | — | 0.2× | 59.3% | 15.0% | 25.4% | 27.5% | 22.5% | — | — |
| TRUP | $1.3B | 67.0× | 43.4× | 0.9× | 11.9% | 16.1% | — | — | — | -0.9× | 37 |
Peers = companies sharing PREJF's sector (Accident & Health Insurance) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 10% of free cash flow, leaving room to grow it and fund buybacks. Last year: $227.7M dividends + $0 buybacks = $227.7M returned on $2.24B FCF.
3 consecutive years of dividend increases · -6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2023
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.12B 100.0% | $5.73B 100.0% | $7.40B 100.0% | $7.37B 100.0% | $7.88B 100.0% | $5.59B 100.0% | $5.67B 100.0% | $5.42B 100.0% | $5.43B 100.0% | $6.48B 100.0% |
| Gross Profit | $1.37B 15.0% | $994.0M 17.4% | $714.0M 9.6% | -$154.0M -2.1% | $147.0M 1.9% | $83.0M 1.5% | $64.0M 1.1% | $535.0M 9.9% | $895.0M 16.5% | $932.0M 14.4% |
| Interest Expense | $57.5M 0.6% | $55.2M 1.0% | $55.6M 0.8% | $39.2M 0.5% | $40.1M 0.5% | $43.2M 0.8% | $42.5M 0.7% | $48.6M 0.9% | $49.0M 0.9% | $49.0M 0.8% |
| Pretax Income | $1.99B 21.8% | -$897.9M -15.7% | $804.2M 10.9% | $241.1M 3.3% | $989.3M 12.6% | -$94.9M -1.7% | $274.4M 4.8% | $496.1M 9.2% | $180.4M 3.3% | $1.29B 20.0% |
| Income Tax Expense | -$327.9M -3.6% | $41.9M 0.7% | $40.0M 0.5% | -$13.1M -0.2% | $52.5M 0.7% | -$8.9M -0.2% | $10.4M 0.2% | $25.9M 0.5% | $79.7M 1.5% | $239.5M 3.7% |
| Net Income | $2.32B 25.4% | -$939.8M -16.4% | $764.2M 10.3% | $254.2M 3.5% | $936.7M 11.9% | -$86.0M -1.5% | $264.0M 4.7% | $447.3M 8.2% | $104.4M 1.9% | $1.05B 16.3% |
| Per Share | ||||||||||
| EPS (Basic) | — | — | — | — | — | — | — | — | $1.00 | $19.96 |
| EPS (Diluted) | — | — | — | — | — | — | — | — | $0.97 | $19.51 |
| Weighted Avg Shares (Basic) | — | — | — | — | — | — | — | — | 47.8M | 50.0M |
| Weighted Avg Shares (Diluted) | — | — | — | — | — | — | — | — | 48.9M | 51.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
A reverse discounted cash flow is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 3-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 3-yr history.
Is the profit real, and how strong is the balance sheet?
FY2023 · every deduction from revenue to net income
DuPont — the three levers
ROE 28% against ROIC 22% — 5% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is 31.3% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | 9.9 | 1.1 | 1.5 | 1.9 | -2.1 | 9.6 | 17.4 | 15.0 |
| Income Tax | 0.5 | 0.2 | -0.2 | 0.7 | -0.2 | 0.5 | 0.7 | -3.6 |
| Net Income | 8.2 | 4.7 | -1.5 | 11.9 | 3.5 | 10.3 | -16.4 | 25.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PREJF: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2014 | 14.4% | not reported | 16.3% |
| FY2015 | 16.5% | not reported | 1.9% |
| FY2016 | 9.9% | not reported | 8.2% |
| FY2017 | 1.1% | not reported | 4.7% |
| FY2018 | 1.5% | not reported | -1.5% |
| FY2019 | 1.9% | not reported | 11.9% |
| FY2020 | -2.1% | not reported | 3.5% |
| FY2021 | 9.6% | not reported | 10.3% |
| FY2022 | 17.4% | not reported | -16.4% |
| FY2023 | 15.0% | not reported | 25.4% |
Leverage and buybacks account for 5 points of the 28% return on equity in FY2023. The business earns 22% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: positive EBIT.
Converts 1.80x of reported profit into cash — adequate, without much margin.
The cash conversion cycle could not be computed — receivables, inventory or cost of revenue is not reported — so the earliest accrual warning is not part of this verdict.
Missing from our data, so excluded from this answer: share_based_compensation.
Leverage is not measurable this way for a insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Missing from our data, so excluded from this answer: capital adequacy metrics for this archetype.
At $15.03, free cash flow must compound -28.07%/yr for 10 years. It has done 44.77%/yr over 6 years, though across a reporting-basis change.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2018 | 84.2% | −28.1% |
| FY2019 | 123.2% | −28.1% |
| FY2020 | 12.6% | −28.1% |
| FY2021 | 9.6% | −28.1% |
| FY2022 | 19.1% | −28.1% |
| FY2023 | 52.3% | −28.1% |
The achieved growth rate spans a reporting-basis change in FY2022, so part of it measures the restatement rather than the business.
| Step | Amount | Running total |
|---|---|---|
| Net income | $2.32B | $2.32B |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | −$82M | $2.24B |
| Operating cash flow | $2.24B | $2.24B |
| Capex | $0 | $2.24B |
| Free cash flow | $2.24B | $2.24B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2018 | -1.5% | not reported | not reported |
| FY2019 | 40.9% | not reported | not reported |
| FY2020 | -6.5% | not reported | not reported |
| FY2021 | 0.5% | not reported | not reported |
| FY2022 | -22.6% | not reported | not reported |
| FY2023 | 59.3% | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2017 | 0.1 percent |
| FY2018 | -2.3 percent |
| FY2019 | -0.3 percent |
| FY2020 | -3.2 percent |
| FY2021 | -1.7 percent |
| FY2022 | -8.8 percent |
| FY2023 | 0.3 percent |